Gene Therapy Restores Hearing in Deaf Patients

Researchers have achieved a significant breakthrough in treating genetic deafness, with a clinical study demonstrating that gene therapy can restore hearing. Ten patients, ranging in age from one to 24, received a single gene therapy injection into their inner ear to address a rare form of congenital deafness caused by OTOF gene mutations. All participants experienced significant hearing improvements, with some regaining the ability to recognize speech within weeks.

This novel approach targets the OTOF gene, crucial for transmitting sound signals to the brain. By delivering a functional copy of the gene via a synthetic virus, the therapy reactivates the natural hearing pathway. Unlike cochlear implants, this method seeks to mend the underlying cellular defect. The therapy proved safe and well-tolerated, with most improvements observed by six months post-treatment.

Previously, treatment for congenital hearing loss, which affects millions globally, was limited to assistive devices. This study, which included teenagers and adults for the first time, marks a pivotal shift towards addressing the genetic cause of deafness directly. Researchers are optimistic that this platform could be expanded to treat other forms of inherited hearing loss, offering a future where genetic deafness may become reversible.